Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a production of Pararotein by non-malignant plasma cells in the absence of other, more typical of multiple myeloma manifestations.

The incidence of MGUS increases of 1% in the age group up to 25 years in> 5% among over-70s. A MGUS can be used in association with other diseases (see table: Division of the plasma cell disorders) arise where paraproteins antibodies may be formed in large amounts in response to a protracted antigenic stimulation.

Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a production of Pararotein by non-malignant plasma cells in the absence of other, more typical of multiple myeloma manifestations. The incidence of MGUS increases of 1% in the age group up to 25 years in> 5% among over-70s. A MGUS can be used in association with other diseases (see table: Division of the plasma cell disorders) arise where paraproteins antibodies may be formed in large amounts in response to a protracted antigenic stimulation. A MGUS runs usually asymptomatic, but can be a peripheral neuropathy occur; In addition, patients have an increased risk for increased bone loss and fractures. Although most cases are initially benign, going up to 25% (1% / year) in a myeloma or similar B-cell disease over such. B. macroglobulinemia, amyloidosis or lymphoma. It usually comes to diagnosis, if by chance discovered in the blood or urine by a routine examination a paraprotein. In the laboratory studies, the paraprotein is at low levels in the serum (<3 g / dl) or urine (<300 mg / 24 h) are present. MGUS and is separated from other plasma cell diseases because the paraprotein levels remain relatively stable over time, and lytic bone lesions, anemia and renal dysfunction did not occur in most cases. Because of the risk of breaking a fundamental analysis with a skeletal evaluation activity (d. H. Simple X-ray images of the skull, long bones, spine, pelvis and ribs) and a bone density test should be performed. The bone marrow shows only a slight plasma cell proliferation (<10% of nucleated cells). Antineoplastic treatment is not recommended. However, recent studies suggest that MGUS patients may benefit bone loss (osteoporosis or osteopenia) from treatment with bisphosphonates. All 6 to 12 months, patients should a clinical examination and an electrophoresis of proteins in serum and urine are subjected to evaluate a possible progression of the disease.

Health Life Media Team

Leave a Reply